Carbetocin is used to prevent excessive bleeding after childbirth by helping the uterus contract and stay firm. It is an alternative to oxytocin (Pitocin) and may be preferred because its effects last longer.[1] Pabal is currently being investigated across 7 indications[3], with its most advanced program in Phase 3.[1]
Pabal is one of 108 small molecule programs targeting Uterine Inertia. It is currently in Phase 3.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
61 competitors in Hemorrhage
Savaysa
Prevacid
Eliquis
Bayer Aspirin
Klor-Con
Plavix
Decadron
Ketalar
Coumadin
Adrenaline
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources
Details